AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 154 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 1.38 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $2,971 | +31.9% | 101,612 | +0.5% | 0.02% | +53.3% |
Q4 2023 | $2,252 | -33.9% | 101,114 | -16.0% | 0.02% | -46.4% |
Q2 2023 | $3,409 | -25.2% | 120,363 | -39.3% | 0.03% | -26.3% |
Q1 2023 | $4,556 | +1056.3% | 198,366 | +1314.4% | 0.04% | +533.3% |
Q4 2022 | $394 | -100.0% | 14,025 | -76.7% | 0.01% | -62.5% |
Q2 2022 | $1,335,000 | -72.5% | 60,238 | -63.8% | 0.02% | -73.8% |
Q1 2022 | $4,846,000 | +1220.4% | 166,459 | +1390.0% | 0.06% | +1425.0% |
Q4 2021 | $367,000 | -68.2% | 11,172 | -55.3% | 0.00% | -75.0% |
Q3 2021 | $1,153,000 | +428.9% | 24,978 | +530.4% | 0.02% | +700.0% |
Q2 2021 | $218,000 | -93.9% | 3,962 | -94.2% | 0.00% | -96.2% |
Q1 2021 | $3,546,000 | +14.3% | 68,673 | -4.1% | 0.05% | +73.3% |
Q4 2020 | $3,102,000 | +197.7% | 71,601 | +140.5% | 0.03% | +42.9% |
Q3 2020 | $1,042,000 | -67.5% | 29,772 | -50.3% | 0.02% | -74.7% |
Q2 2020 | $3,204,000 | +276.5% | 59,908 | +374.7% | 0.08% | +31.7% |
Q1 2019 | $851,000 | – | 12,621 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |